Peer-reviewed veterinary case report
Test to detect anti-asparaginase antibodies in dogs with lymphoma
By Kidd, J A et al.·Published in Veterinary and comparative oncology·2015·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma (a type of cancer) was treated with a medication called Escherichia coli l-asparaginase. Researchers developed a test to check if these dogs were producing antibodies against the drug, which could make it less effective over time. They found that some dogs developed these antibodies after just one injection, and more did so after multiple doses. This test could help veterinarians understand how these antibodies affect treatment success and resistance to the medication.
People also search for: dog lymphoma treatment · l-asparaginase side effects in dogs · why is my dog not responding to cancer treatment
Abstract
Resistance to Escherichia coli l-asparaginase in canine lymphoma occurs frequently with repeated administration, a phenomenon often attributed, without substantiation, to the induction of neutralizing antibodies. To test the hypothesis that treated dogs develop antibodies against the drug, we created an enzyme-linked immunosorbent assay (ELISA) to measure plasma anti-asparaginase immunoglobulin G responses. Using samples from dogs that had received multiple doses, specific reactivity against l-asparaginase was demonstrated, while naïve patients' samples were negative. The optimized ELISA appeared sensitive, with endpoint titers >1 600 000 in positive control dogs. Intra- and inter-assay coefficients of variation were 3.6 and 14.5%. The assay was supported by the observation that ELISA-positive plasma could immunoprecipitate asparaginase activity. When clinical patients were evaluated, 3/10 dogs developed titers after a single injection; with repeated administration, 4/7 dogs were positive. l-asparaginase antibodies showed reduced binding to the PEGylated drug formulation. The ELISA should prove useful in investigating the potential correlation of antibody responses with resistance.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23253146/